Latest news with #ATR
New Indian Express
8 hours ago
- General
- New Indian Express
IndiGo's Ahmedabad-Diu flight aborts take-off due to technical snag; DGCA launches probe
AHMEDABAD: An IndiGo flight bound for Diu was forced to abort take-off after a cockpit engine fire alert triggered panic. This near-miss comes just over a month after the deadly crash of Air India flight AI-171, which killed 260 people, including those on board and on the ground. Flight 6E-7966, operated on an ATR aircraft (VT-IYA), was preparing to take off from Ahmedabad when pilots suddenly received an 'engine one flameout' warning. Reacting swiftly, the crew rejected take-off and brought the aircraft to a safe halt. All 70 passengers and crew members on board escaped unhurt. The aircraft has now been grounded for detailed checks. Meanwhile, the Directorate General of Civil Aviation (DGCA) has launched a formal probe into the incident, aiming to determine what triggered the fire alert. Reacting on the incident , An IndiGo Spokesperson says, "A technical snag indication was noticed just before take-off on IndiGo flight 6E7966 operating from Ahmedabad to Diu on 23 July 2025. Following the standard operating procedure, the pilots informed the authorities and returned the aircraft to bay. The aircraft will undergo necessary checks and maintenance before resuming operations."
Hamilton Spectator
13 hours ago
- Business
- Hamilton Spectator
Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening
VANCOUVER, British Columbia, July 23, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. ('Rakovina' or the 'Company') (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced meaningful progress in its AI-driven KT-5000AI program, advancing the development of precision ATR (Ataxia Telangiectasia and Rad3-related) inhibitors designed to disrupt the DNA Damage Response pathway in cancer cells. Through its collaboration with Variational AI , Rakovina Therapeutics evaluated a vast chemical space of potential molecular structures using artificial intelligence to identify novel compounds designed to selectively inhibit ATR. A subset of these AI-generated candidates has been synthesized and has advanced through initial biological screening, with multiple compounds demonstrating potent ATR inhibition in nanomolar concentration range. The most promising candidates are being prioritized for further characterization and potential development. 'The progress we're seeing in the KT-5000AI program highlights the advantage of combining artificial intelligence with modern drug design,' said Dr. Mads Daugaard, Rakovina's President and Chief Scientific Officer. 'We're particularly encouraged by the number of active compounds emerging from the first wave of screening and look forward to advancing the most promising candidates through further evaluation and development.' ATR inhibitors represent a fast-growing class of oncology therapeutics, with the global ATR inhibitor market valued at approximately US $1.24 billion in 2024, expanding at a compound annual growth rate (CAGR) of nearly 17.8% through 2033, with forecasts projecting a market size of over US $5.1 billion by 2033 (source: Growth Markets Reports ). This growth is fueled by increasing validation of ATR as an oncology target, rising need for therapies addressing replication stress and DNA repair–deficient tumors, and a shift toward personalized, AI-enabled drug development. Rakovina's KT-5000AI series is well-positioned to capture value in this expanding landscape by delivering next-generation compounds with improved selectivity, potency, and therapeutic index. About Rakovina Therapeutics Inc. Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at . Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Rakovina Therapeutics Forward-Looking Statements: This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans,' 'is expected,' 'expects,' 'scheduled,' 'intends,' 'contemplates,' 'anticipates,' 'believes,' 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may,' 'could,' 'would,' 'might,' or 'will' be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company's most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company's profile page at . For Further Information Contact: Michelle Seltenrich, BSc MBA Director, Corporate Development IR@ 778-773-5432
Toronto Star
13 hours ago
- Business
- Toronto Star
Rakovina Therapeutics KT-5000AI Program Yields Potent ATR Inhibitor Hits in Early Screening
VANCOUVER, British Columbia, July 23, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. ('Rakovina' or the 'Company') (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced meaningful progress in its AI-driven KT-5000AI program, advancing the development of precision ATR (Ataxia Telangiectasia and Rad3-related) inhibitors designed to disrupt the DNA Damage Response pathway in cancer cells. Through its collaboration with Variational AI, Rakovina Therapeutics evaluated a vast chemical space of potential molecular structures using artificial intelligence to identify novel compounds designed to selectively inhibit ATR. A subset of these AI-generated candidates has been synthesized and has advanced through initial biological screening, with multiple compounds demonstrating potent ATR inhibition in nanomolar concentration range. The most promising candidates are being prioritized for further characterization and potential development.
The Star
2 days ago
- Business
- The Star
Mavcom to hand over regulatory functions to CAAM from Aug 1
Mavcom executive chairman Datuk Seri Saripuddin Kasim KUALA LUMPUR: The Malaysian Aviation Commission (Mavcom) will transfer its regulatory functions and responsibilities over to the Civil Aviation Authority of Malaysia (CAAM) from Aug 1, 2025. In a statement, Mavcom said the rationalisation of the two entities - which was announced by the Minister of Transport in June - will be implemented in accordance with the Malaysian Aviation Commission (Dissolution) Act 2024 [Act 856]. The functions assumed by CAAM will include, but are not limited to, licensing, allocation of Air Traffic Rights (ATR), airport development, Rural Air Services (RAS), economics and competition matters, as well as general regulatory oversight. CAAM will also oversee the management of digital platforms such as AeroFile and AeroLicence for processing overflight and landing permits, as well as licensing applications. Stakeholders are encouraged to visit for the latest updates and to access these services "Our priority is to ensure a smooth and seamless transition with minimal disruption to stakeholders and the public. The sustainability and continued growth of Malaysia's aviation industry remain at the forefront of our efforts throughout this process," said Mavcom executive chairman Datuk Seri Saripuddin Kassim. All Mavcom's consumer platforms will remain fully operational during and after Aug 1, 2025. Consumers may continue to lodge complaints on airlines or airports through the existing FlySmart website and mobile app. Any future updates to contact information will be communicated via CAAM's official channels.
Mint
2 days ago
- Business
- Mint
More complaints pending with Sebi than it resolved last month, reveals latest SCORES data
When investors encounter any problem relating to stock markets or a listed company, they can first approach the entity concerned. Later, when the problem does not get resolved, they can file a complaint with SCORES, which is online grievance redressal platform provided by the capital markets regulator Sebi. The regulator recently shared the latest data with regards to the number of complaints that were resolved and pending at the end of June 2025. The data reveals that there are 5,107 pending complaints in comparison to 4,563 that were pending a month ago. This means an increase of 11.9 percent in the number of complaints filed. Particulars Data Complaints pending on May 31 4,563 Complaints received during June 4,959 Pending on June 30, 2025 5,107 Complaints disposed during June 2025 4,415 Average resolution time (in days) ATR 8 Complaints disposed during June stand at 4,415 which is 10 percent less than the number of complaints received (4,959) during this time. Additionally, average resolution time in the number of days for issuing action taken report (ATR) stood at eight days in June, reveals Sebi data. 1. Complaints are automatically forwarded to entity which is given 21 days to submit the action taken report (ATR) to investor. 2. Investor can opt for the first-level review within 15 days if not satisfied with the ATR. The complaint is shown in the pending list for 15 days despite ATR is submitted by entity. 3. If investor does not opt for review, the complaint is disposed off. If investor opts for first-level review, the designated body will take up the complaint and submit action taken report. 4. Now, the investor will have a time of 15 days to opt for second level review if not satisfied with the ATR submitted by designated body. The complaint is shown in pending list for 15 days despite ATR is submitted by Designated Body. 5. Now, when the investor does not go for the review, the complaint is then disposed. 6. However, if investor now goes for the second level review, the SEBI will take up the complaint and submit action taken report. 7. Complaint is also treated as disposed if the investor opts for Online Disputes Redressal (ODR) mechanism. For all personal finance updates, visit here
